Acumen Pharmaceuticals, Inc.
ABOS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001576885
No open-market purchases or sales by Acumen Pharmaceuticals, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $127.8M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Acumen Pharmaceuticals, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 60 | 62 | +2 |
| Shares | 28.7M | 27.8M | −971.8K (−3.4%) |
| Value | $155.1M | $112.8M | −$42.4M (−27.3%) |
New holders (10)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| J. Goldman & Co LP | 135,000 | $548.1K | 0.03% |
| Dimensional Fund Advisors LP | 66,779 | $271.1K | 0.00% |
| UBS Oconnor LLC | 61,358 | $249.1K | 0.01% |
| Squarepoint Ops LLC | 19,343 | $78.5K | 0.00% |
| LMR Partners LLP | 16,892 | $68.6K | 0.00% |
| Citadel Advisors LLC | 14,081 | $57.2K | 0.00% |
| Point72 Asset Management, L.P. | 3,954 | $16.1K | 0.00% |
| Point72 Middle East FZE | 3,415 | $13.9K | 0.00% |
| UBS Group AG | 3,137 | $12.7K | 0.00% |
| Kelly Financial Services LLC | 944 | $3.83K | 0.00% |
Sold out (8)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Perceptive Advisors LLC | 347,450 | $1.88M |
| Bank of Montreal | 58,400 | $325.9K |
| Cheyne Capital Management (UK) LLP | 55,829 | $301.5K |
| Moore Capital Management, LP | 27,578 | $148.9K |
| Acadian Asset Management LLC | 15,741 | $85.0K |
| Lighthouse Investment Partners, LLC | 11,263 | $60.8K |
| Dynamic Technology Lab Private Ltd | 10,525 | $57.0K |
| Ellevest, Inc. | 257 | $1.39K |